Newsroom

Our latest developments

Orca Bio’s announcements and press releases

First Clinical Data From Ongoing Orca-T Trial Shows Significantly Improved 12-Month Graft Versus Host Disease (GvHD)-Free and Relapse-Free Survival (GRFS) in Blood Cancer Patients Receiving a Hematopoietic Stem Cell Transplant (HSCT)

View

Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting

View

Orca Bio Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Orca-T

View

Orca Bio and Lyell Immunopharma Announce Research Partnership

View

Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy

View

Orca Bio's fact sheets

No posts found.

For media inquiries,

contact us at:

media@orcabio.com
NEXT: Discover who we are